A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer

Immunomedics, Inc.0 个研究点目标入组 600 人开始时间: 2021年4月2日最近更新: 2024年7月15日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: Immunomedics, Inc.
入组人数: 600

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•1. Female or male subjects, = 18 years of age, able to understand and give written informed consent.
•2. Subjects with histologically documented metastatic or locally advanced unresectable UC defined as:
•Tumor (T) 4b, any node (N) or
•Any T, N 2-3
•Tumors of upper and lower urinary tract are permitted. Mixed histologic types are allowed if urothelial is the predominant histology.
•3. ECOG PS score of 0 or 1.
•4. Subjects with progression or recurrence following receipt of platinum-containing regimen and anti PD-1/PD-L1 therapy for metastatic or locally advanced unresectable disease will be enrolled.
•a. Subjects with recurrence or progression = 12 months following completion of cisplatin-containing chemotherapy given in the neoadjuvant/ adjuvant setting may utilize that line of therapy to be eligible for the study. The 12-month period is counted from completion of surgical intervention or platinum therapy, respectively. These subjects must receive anti PD-1/PD-L1 therapy in the metastatic or locally advanced unresectable setting to be eligible.
•b. Subjects who received either carboplatin or anti PD-1/PD-L1 therapy in the neoadjuvant/ adjuvant setting will not be able to count that line of therapy towards eligibility for the study.
•c. Cisplatin ineligible subjects who meet one of the below criteria and who were treated with carboplatin in the metastatic or locally advanced unresectable settings may count that line of therapy towards eligibility. They must then have received anti PD-1/PDL1
•therapy in metastatic or locally advanced unresectable setting to be eligible for the study.
•Cisplatin ineligibility is defined as meeting one of the following criteria:
•1. Creatinine Clearance <60 mL/min
•2. Grade =2 Audiometric Hearing Loss
•3. Grade =2 Peripheral Neuropathy
•4. New York Heart Association (NYHA) Class III heart failure
•5. ECOG PS =2
•d. Anti PD-1/PD-L1 therapy administered as part of maintenance therapy may be counted towards eligibility for the study
•e. Subjects who received only concurrent chemoradiation for bladder preservation without further systemic therapy are not eligible to enroll in the study. The substitution of carboplatin for cisplatin does not constitute a new regimen provided no new chemotherapeutic agents were added to the regimen and no progression was noted prior to the change in platinum.
•5. Subjects with previously treated brain metastases may participate in the study provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and stabilization of all neurologic symptoms, have no evidence of new or enlarging brain metastases, and are not using steroids > 20 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to first dose of the study drug.
•6. Adequate hematologic counts without transfusion or growth factor support within 1 week of study drug initiation (hemoglobin = 9 g/dL, absolute neutrophil count [ANC] = 1,500/mm3, and platelets = 100,000/µL).
•7. Adequate hepatic function (bilirubin = 1.5x institutional upper limit of normal [IULN], aspartate aminotransferase [AST] and alanine aminotransferase [ALT] = 2.5 x IULN or = 5 x IULN if known liver metastases and serum albumin > 3 g/dL).
•Docetaxel will only be an option in TPC arm for subjects with a total bilirubin = 1 x IULN, and an AST and/or ALT = 1.5x IULN if alkaline phosphatase is also > 2.5 x IULN.
•8. Creatinine clearance = 30 mL/min as assessed by the Cockcroft-Gault equation or other val

排除标准

•- Have had a prior anti-cancer mAb/ADC within 4 weeks prior to C1D1 or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to C1D1. Subjects participating in observational studies are eligible.
•- Have received prior chemotherapy for urothelial cancer with all available SOC therapies in the control arm (i.e., both prior paclitaxel and docetaxel in regions where vinflunine is not an approved therapy, or prior paclitaxel, docetaxel and vinflunine in regions where vinflunine is an approved therapy).
•- Have not recovered (i.e., = Grade 1) from AEs due to previously administered chemotherapeutic agent.
•Note: Subjects with = Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study.
•Note: If subjects received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study therapy.
•- Have previously received topoisomerase 1 inhibitors.
•- Have an active second malignancy.
•Note: Subjects with a history of malignancy that have been completely treated and with no evidence of active cancer for 3 years prior to enrollment, or subjects with surgically cured tumors with low risk of recurrence are allowed to enroll in the study after discussion with the medical monitor.
•- Have an active serious infection requiring anti-infective therapy (Contact medical monitor for clarification).
•- Have inability to tolerate or are allergic to any potential TPC agent or sacituzumab govitecan or unable or unwilling to receive the doses specified in the protocol.

研究者

发起方

Immunomedics, Inc.

相似试验

招募中

3 期

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer

2024-513870-23-00Gilead Sciences Inc.391

进行中（未招募）

1 期

A study to compare study medication Sacituzumab Govitecan with Standardof Care medications (Paclitaxel, Docetaxel or Vinflunine) in Metastatic (spread to other locations in the body) or Locally Advanced Unresectable (cannot be removed surgically) Urothelial (urinary system) Cancer which has progressed or returned after prior treatments with platinum containing chemotherapy and immunotherapyMetastatic or Locally Advanced Unresectable Urothelial CancerMedDRA version: 21.1Level: LLTClassification code 10077840Term: Urothelial cancer of renal pelvisSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000004864

EUCTR2020-002964-29-HRGilead Sciences Inc696

进行中（未招募）

1 期

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer

EUCTR2020-002964-29-ATGilead Sciences Inc600

进行中（未招募）

1 期

A study to compare study medication Sacituzumab Govitecan with Standardof Care medications (Paclitaxel or Docetaxel) in Metastatic (spread to other locations in the body) or Locally Advanced Unresectable (cannot be removed surgically) Urothelial (urinary system) Cancer which has progressed or returned after prior treatments with platinum containing chemotherapy and immunotherapyMetastatic or Locally Advanced Unresectable Urothelial CancerMedDRA version: 21.1Level: LLTClassification code 10077840Term: Urothelial cancer of renal pelvisSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046723Term: Urothelial carcinoma ureterSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10046728Term: Urothelial carcinoma urethraSystem Organ Class: 100000004864

EUCTR2020-002964-29-BGGilead Sciences Inc696

进行中（未招募）

1 期

EUCTR2020-002964-29-IEGilead Sciences Inc600